Physiomics plc (LSE:PYC) has been awarded a new contract by a South Korea-based clinical-stage biopharma group focused on next-generation antibody-drug conjugates and immuno-oncology treatments. Valued at up to £66,600, the assignment will involve applying pharmacokinetic and pharmacodynamic (PK/PD) modelling and simulation to support dose selection for one of the client’s oncology candidates. The work is set to begin immediately and is expected to conclude within two months.
The agreement expands Physiomics’ footprint in Asia and aligns with its strategy to grow its international client base beyond core markets. It also reflects increasing demand for advanced quantitative modelling tools to reduce risk and improve decision-making in cancer drug development. Management described the mandate as further evidence of the company’s ability to deliver data-driven insights at pivotal clinical stages, where accurate dose optimisation can materially influence outcomes.
Despite the strategic progress, the company’s broader outlook continues to be shaped by financial challenges. Persistent losses and ongoing cash outflows weigh on performance, even as revenues showed a rebound in 2025 and the balance sheet remains debt-free. Technical indicators offer a more constructive picture, with the share price trading above key moving averages, though overbought signals suggest potential short-term volatility. Valuation metrics remain constrained by negative earnings and the lack of dividend support.
More about Physiomics plc
Physiomics plc is a UK-based specialist in mathematical modelling, biostatistics and data science, supporting biotechnology and pharmaceutical companies in the development of new medicines and personalised therapies. Through computational approaches, custom-built models and its proprietary Virtual Tumour platform, the company helps streamline drug development across discovery, pre-clinical and clinical phases. Its client roster includes Merck KGaA, Astellas and Bicycle Therapeutics.
Leave a Reply